Maven Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Maven Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,588	Closed	-$788K	–	1121
2021 Q4	$788K	Buy	+3,588	New	+$698K	0.02%	426
2021 Q2	–	Sell	-4,328	Closed	-$905K	–	1357
2021 Q1	$931K	Buy	4,328 +528	+14%	+$116K	0.04%	449
2020 Q4	$898K	Buy	3,800 +763	+25%	+$175K	0.09%	266
2020 Q3	$830K	Buy	3,037 +2,283	+303%	+$630K	0.07%	279
2020 Q2	$219K	Sell	754 -646	-46%	-$175K	0.02%	485
2020 Q1	$333K	Buy	+1,400	New	+$321K	0.04%	216
2017 Q1	–	Sell	-219	Closed	-$16K	–	64
2016 Q4	$16K	Buy	+219	New	+$17.8K	0.01%	43

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Maven Securities's VRTX Position: Q1 2022 in Review

Maven Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 3,588 shares — an estimated $788K sold.

Maven Securities first reported a position in VRTX in Q4 2016 and held it in 7 quarters. The position peaked at $931K in Q1 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Maven Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Maven Securities sold 3,588 Vertex Pharmaceuticals shares in Q1 2022, an estimated $788K.
Maven Securities first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Maven Securities's Vertex Pharmaceuticals position peaked at $931K in Q1 2021.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.